Medical Innovation Exchange

BMS, J&J's secondary stroke med falls short in phase 2 but companies see enough potential to push forward

https://www.fiercebiotech.com/biotech/bms-secondary-stroke-med-doesnt-stick-ph-2-landing-encouraging-data-tees-future-trial

Leave a Comment

Your email address will not be published.

Leave the field below empty!